Vincerx Pharma Announces Pricing of Underwritten Public Offering of Common Stock and Warrants
April 26, 2024 00:27 ET
|
Vincerx Pharma, Inc.
PALO ALTO, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC) today announced the pricing of an underwritten public offering of (i) 6,000,000 shares of its common stock...
Vincerx Pharma Announces Proposed Underwritten Public Offering of Common Stock and Warrants
April 25, 2024 16:01 ET
|
Vincerx Pharma, Inc.
PALO ALTO, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC) today announced a proposed underwritten public offering of shares of its common stock and accompanying...
Vincerx Pharma Presents Positive Preliminary Phase 1 Data for VIP236 and Updates on Pipeline Progress at the American Association for Cancer Research (AACR) Annual Meeting 2024
April 08, 2024 16:30 ET
|
Vincerx Pharma, Inc.
VIP236 demonstrated positive signs of clinical activity, including tumor reduction, and an improved safety profile in heavily pretreated patients with metastatic solid tumors VIP943 pharmacokinetic...
Vincerx to Host Virtual Investor Event Reviewing Preliminary Phase 1 VIP236 Data Presented at the American Association for Cancer Research (AACR) Annual Meeting 2024
April 01, 2024 08:00 ET
|
Vincerx Pharma, Inc.
PALO ALTO, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through...
Vincerx Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Update
March 29, 2024 15:20 ET
|
Vincerx Pharma, Inc.
VIP236, first-in-class small molecule-drug conjugate (SMDC), preliminary Phase 1 data and update on pipeline progress will be presented by management at a virtual investor event on April 8 at 2:00 PM...
Vincerx to Present Three Posters at the American Association for Cancer Research (AACR) Annual Meeting 2024
March 05, 2024 16:31 ET
|
Vincerx Pharma, Inc.
PALO ALTO, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through...
Vincerx Pharma Announces Compelling Clinical Efficacy of Enitociclib in Combination with Venetoclax and Prednisone in Lymphoma
January 07, 2024 15:00 ET
|
Vincerx Pharma, Inc.
Investigators from the National Institutes of Health (NIH) report 2 partial responses (PR) in 3 peripheral T-cell lymphoma (PTCL) patients and 1 PR in 2 double-hit diffuse large b-cell lymphoma...
Vincerx Pharma Presents Preclinical VIP943 and VIP924 Posters at ASH 2023
December 10, 2023 12:00 ET
|
Vincerx Pharma, Inc.
Poster on VIP943, a novel CD123-targeted antibody-drug conjugate (ADC) from our VersAptx™ platform, showcases selectivity, activity, and safety of VIP943 Poster on VIP924, a first-in-class...
Vincerx Pharma Reports Third Quarter 2023 Financial Results and Provides Corporate Update
November 14, 2023 07:00 ET
|
Vincerx Pharma, Inc.
Phase 1 dose escalation for VIP943 - first antibody-drug conjugate (ADC) from VersAptx™, versatile and adaptable, next-generation bioconjugation platform - moves quickly into 2nd cohort Phase 1 dose...
Vincerx Pharma To Present Three Posters at ASH 2023 in December
November 02, 2023 09:10 ET
|
Vincerx Pharma, Inc.
VIP943 poster supports selectivity and safety of lead CD123 ADC, VIP943, currently in Phase 1 VIP924 poster shows this novel CXCR5-ADC compares favorably with other ADCs in clinical development ...